Mayo Acute Stroke Trial for Enhancing Recovery (MASTER)

Mayo Clinic

Status and phase: Completed; Phase 2

Conditions: Ischemic Stroke

Treatments: Drug: Donepezil

Study type: Interventional

Funder types: Other

Identifiers

NCT00805792

08-005098

Details and patient eligibility

About

This study involves treating patients that have suffered an acute ischemic stroke with the medication donepezil (Aricept ®). The hypothesis is that taking donepezil (FDA-approved for the treatment of Alzheimer's Disease) for the first 90 days following a stroke enhances recovery.

Full description

We hypothesize that donepezil (5 mg per day, titrated up to 10 mg per day as tolerated) will enhance recovery following stroke by improving attention, learning and memory thereby enhancing rehabilitation. The null hypothesis is that the probability of a favorable outcome among post-stroke donepezil users is equal to that observed among similar participants in an existing National Institutes of Neurological Disorders and Stroke (NINDS) resource, the Phase III clinical trial of Tissue Plasminogen Activator (tPA) for acute ischemic stroke. The NINDS tPA stroke trial has been used as historical control data in pilot trials of reperfusion and neuroprotection.

The MASTER trial will be a multicenter, single-arm NINDS Recominant tPA trial-controlled, modified 2-stage adaptive clinical trial set in 2 tertiary care hospitals in the United States. Participants will be men and women with acute (< 24 hours of onset of symptoms) ischemic stroke. A favorable outcome will be defined as National Institutes of Health Stroke Scale (NIHSS) values of 0 or 1 at 90 days post-stroke.

Enrollment: 33 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Definite or probable acute ischemic cerebrovascular syndrome (AICS), as defined by Kidwell et al (Stroke. 2003;34:2995-8).
• Experimental treatment started within 24 hours of onset of symptoms.
• Age ≥ 18 years.
• Ability and willingness to return for follow-up visits.
• Willingness of an available informant who knows the patient well to participate in informant-based questionnaires for the duration of the follow-up period.
• Living in independent or semi-independent living situation before the stroke.
• Fluent in English before the stroke.
• Provides written informed consent.
• Near visual acuity of at least 20/200 in at least one eye.
• Auditory acuity of at least having the ability to detect finger rubbing in at least one ear.

Exclusion criteria

• Parkinson's disease or restless leg syndrome.
• Partial or generalized seizures.
• No acute decompensated heart failure
• Routinely requiring daytime supplemental oxygen before the stroke; study participants on continuous positive air pressure (CPAP) for obstructive sleep apnea remain eligible.
• Gastrointestinal or genitourinary surgery within 1 month of screening.
• Gastrointestinal bleeding.
• Syncope or symptomatic bradycardia.
• Creatinine ≥ 3.5 mg/dL or requiring dialysis.
• Peptic ulcer disease.
• Asthma.
• Tracheostomy or endotracheal intubation.
• Taking donepezil or other acetylcholinesterase inhibitor at screening.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

33 participants in 1 patient group

Donepezil

Experimental group

Description:

Participants received treatment with donepezil within 24 hours after the onset of ischemic stroke symptoms. Participants received donepezil 5 mg/day for 30 days, followed by an increase to 10 mg/day for 60 days.

Treatment:

Drug: Donepezil